MRI scans to monitor low-risk prostate cancer in active surveillance
Part of Cancer, Kidney & urinary clinical trials.
This trial uses special MRI scans to help track low-risk prostate cancer while you stay on active surveillance (meaning no immediate treatment). It may help your care team better understand changes in the cancer over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-risk prostate cancer that is being followed with active surveillance
- You can complete a multiparametric MRI scan with usable scan data
- You have not had prostate cancer treatment before joining
- You have no known serious allergy to MRI contrast dye (gadolinium)
- You can have MRI safely: no pacemaker, no metal fragments/residues, and you can tolerate the MRI space
- You have normal kidney function for contrast (GFR 30 or higher), and you have not had a prostate biopsy in the last 21 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a special MRI scan (with multiple measurements) may help men with low-risk prostate cancer who are monitoring it closely instead of treating right away. It may help doctors better understand the cancer’s status during active surveillance.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
This study uses special prostate MRI scans to see how prostate cancer changes over time while you stay on active surveillance. It also looks at prostate tissue to understand your cancer’s genetics, which may help guide future decisions.
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
This trial uses repeated MRI scans to monitor prostate lesions that have a low chance of being aggressive cancer. It is for people who have suspicious spots but whose initial biopsies did not find high-grade cancer.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.